

KEY:

Strongly Agree / Very Good	Agree / Good	Neutral	Disagree / Poor	Strongly Disagree / Very poor
5	4	3	2	1

Session 1A – New biomarkers for predicting outcome in CTCL

Learning Objectives:

1. Apply new biomarkers to understanding of prognosis in CTCL
2. Clarify relationship of dupilumab and risk of CTCL progression

*PLEASE CIRCLE YOUR RATING
FOR EACH PRESENTER
(see KEY at top of page)*

	Met the stated learning objectives	Was unbiased and offered a balanced perspective	Improved my knowledge / understanding of the topic	Was relevant to my practice	Provided opportunity for individual / group interaction
Andy Li	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1
Safa Nadjidh	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1
Pan Lai	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1
Pablo Ortiz-Romero	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1
Yu Xiao	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1
Mingjia Li	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1
Abigail Fleischli	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1

Which CanMEDS do you feel were covered by these topics? Select all that apply:

☐ Medical Expert ☐ Communicator ☐ Collaborator ☐ Health Advocate ☐ Leader ☐ Professional ☐ Scholar

What did you learn or how will this session impact your practice? _____

Additional Comments: _____

Session 1B – From Novel Topicals to Real-world Outcomes

Learning Objectives:

1. Apply emerging clinical trial data on novel topical therapies to the management of early-stage cutaneous T-cell lymphoma.
2. Analyze long-term clinical trajectories and relapse patterns in indolent B-cell lymphomas and CD4+ LPD based on large-scale cohort studies and real-world evidence.
3. Identify key risk factors and complications, such as second primary malignancies and folliculotropism, to improve long-term survivorship care.

*PLEASE CIRCLE YOUR RATING
FOR EACH PRESENTER*

	Met the stated learning objectives	Was unbiased and offered a balanced perspective	Improved my knowledge / understanding of the topic	Was relevant to my practice	Provided opportunity for individual / group interaction
Ellen J. Kim	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1
Julia Dai	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1
Silvia Alberti-Violetti	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1
Toan Bui	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1
Lauren Banner	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1
Neenu Sebastian	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1
Robert Stuver	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1

Which CanMEDS do you feel were covered by these topics? Select all that apply:

☐ Medical Expert ☐ Communicator ☐ Collaborator ☐ Health Advocate ☐ Leader ☐ Professional ☐ Scholar

What did you learn or how will this session impact your practice? _____

Additional Comments: _____

KEY:

Strongly Agree / Very Good	Agree / Good	Neutral	Disagree / Poor	Strongly Disagree / Very poor
5	4	3	2	1

Session 2 – Risk, Disparities, and Prognostic Determinants in Cutaneous T-Cell Lymphoma

Learning Objectives:

1. Identify clinical and biologic high-risk features in early-stage mycosis fungoides and Sézary syndrome.
2. Analyze racial, ethnic, and socioeconomic disparities affecting diagnosis, disease severity, and outcomes in CTCL.
3. Apply emerging diagnostic and biologic tools to improve risk stratification and promote equitable care in patients with CTCL

<i>PLEASE CIRCLE YOUR RATING FOR EACH PRESENTER</i>	Met the stated learning objectives	Was unbiased and offered a balanced perspective	Improved my knowledge / under-standing of the topic	Was relevant to my practice	Provided opportunity for individual/group interaction
Julia J. Scarisbrick	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1
Pamela B. Allen	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1
Abraham E. Bashir	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1
Liliana L. Crisan	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1
Hadar K. Shimshon	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1
Rocío Millán	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1
Kofi Owusu-Ansah	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1

Which CanMEDS do you feel were covered by these topics? Select all that apply:

☐ Medical Expert ☐ Communicator ☐ Collaborator ☐ Health Advocate ☐ Leader ☐ Professional ☐ Scholar

What did you learn or how will this session impact your practice? _____

Additional Comments: _____

ACCREDITED SYMPOSIUM: The Importance of Durability of Response in Managing CTCL

Learning Objectives:

1. Recognize clinical trial data and real-world evidence evaluating durability-related endpoints across systemic treatment options, with a particular focus on time to next treatment (TTNT) as a pragmatic and clinically meaningful measure of long-term benefit.
2. Outline how TTNT captures both treatment effectiveness and tolerability in routine clinical practice.
3. Evaluate the role of TTNT in treatment sequencing, long-term management strategies, and patient-centric decision-making in advanced CTCL.

<i>PLEASE CIRCLE YOUR RATING FOR EACH PRESENTER</i>	Met the stated learning objectives	Was unbiased and offered a balanced perspective	Improved my knowledge / under-standing of the topic	Was relevant to my practice	Provided opportunity for individual/group interaction
Julia J. Scarisbrick	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1
Jan Nicolay	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1

Which CanMEDS do you feel were covered by these topics? Select all that apply:

☐ Medical Expert ☐ Communicator ☐ Collaborator ☐ Health Advocate ☐ Leader ☐ Professional ☐ Scholar

What did you learn or how will this session impact your practice? _____

Additional Comments: _____

KEY:

Strongly Agree / Very Good	Agree / Good	Neutral	Disagree / Poor	Strongly Disagree / Very poor
5	4	3	2	1

Plenary Session – Herschel S. Zackheim Lectureship: 40 Year of Research on Skin Immunity

Learning Objectives:

1. Identify the different variants of CTCL, including Mycosis Fungoides and Sezary
2. Apply fundamental immunology knowledge to understanding diseases
3. Understand how to approach treatment for CTCL rationally
4. Consider / Evaluate potential new approaches to diagnosis and treatment

*PLEASE CIRCLE YOUR RATING
FOR EACH PRESENTER*

	Met the stated learning objectives	Was unbiased and offered a balanced perspective	Improved my knowledge / understanding of the topic	Was relevant to my practice	Provided opportunity for individual/group interaction
Thomas S. Kupper	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1

Which CanMEDS do you feel were covered by these topics? Select all that apply:

☐ Medical Expert ☐ Communicator ☐ Collaborator ☐ Health Advocate ☐ Leader ☐ Professional ☐ Scholar

What did you learn or how will this session impact your practice? _____

Additional Comments: _____

Session 3A – T cells Gone Rogue: Single-Cell, Spatial, and Molecular Frontiers in CTCL

Learning Objectives:

1. Describe the lesion-specific immune, stromal, and microbiomic landscapes of Mycosis Fungoides as revealed by single-cell proteomic, transcriptomic, and multi-omics approaches.
2. Integrate emerging data on T-cell clonal dynamics, checkpoint-dominated microenvironments, and immunosuppressive mechanisms to better understand disease progression and treatment response in CTCL.
3. Apply novel biomarkers and AI-based tools — including deep-learning T-cell recognition and molecular profiling of treatment-exposed lesions — to inform prognosis and therapeutic decision-making in Mycosis Fungoides.

*PLEASE CIRCLE YOUR RATING
FOR EACH PRESENTER*

	Met the stated learning objectives	Was unbiased and offered a balanced perspective	Improved my knowledge / understanding of the topic	Was relevant to my practice	Provided opportunity for individual/group interaction
Eleni-Kyriaki Vetsika	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1
Pieter A. Valkema	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1
Patrick Brunner	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1
Katherine de Jong	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1
Laura C. Schultz	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1
Evangelia Papadavid	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1
Eleanor Ostroff	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1

Which CanMEDS do you feel were covered by these topics? Select all that apply:

☐ Medical Expert ☐ Communicator ☐ Collaborator ☐ Health Advocate ☐ Leader ☐ Professional ☐ Scholar

What did you learn or how will this session impact your practice? _____

Additional Comments: _____

KEY:

Strongly Agree / Very Good	Agree / Good	Neutral	Disagree / Poor	Strongly Disagree / Very poor
5	4	3	2	1

Session 3B: Optimizing Mogamulizumab Therapy in Cutaneous T-Cell Lymphomas: Real-World Evidence, Safety, and Long Term Outcomes

Learning Objectives:

1. Evaluate real-world and on the effectiveness of mogamulizumab in patients with mycosis fungoides and Sézary syndrome, including comparative outcomes versus clinical trial evidence and standard therapies.
2. Assess management strategies associated with mogamulizumab treatment, including retreatment following adverse events such as drug-related rash.
3. Interpret long-term outcomes and treatment sequencing strategies, including discontinuation and retreatment approaches, to inform clinical decision-making in relapsed or refractory disease

<i>PLEASE CIRCLE YOUR RATING FOR EACH PRESENTER</i>	Met the stated learning objectives	Was unbiased and offered a balanced perspective	Improved my knowledge / under-standing of the topic	Was relevant to my practice	Provided opportunity for individual/group interaction
Gabrielle Rocuzzo	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1
Amy Liao	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1
Marie Beylot-Barry	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1
Lena Specht	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1
H. Miles Prince	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1

Which CanMEDS do you feel were covered by these topics? Select all that apply:

☐ Medical Expert ☐ Communicator ☐ Collaborator ☐ Health Advocate ☐ Leader ☐ Professional ☐ Scholar

What did you learn or how will this session impact your practice? _____

Additional Comments: _____

Session 4A – Contemporary Advances in Cutaneous T-Cell Lymphomas. New Frontiers in Cutaneous Lymphoma Diagnosis and Prognosis

Learning Objectives:

1. Apply recent clinico-pathological and prognostic insights (e.g. lesional BSA thresholds, TFH phenotype, co-occurring lymphomas) to refine the diagnosis and risk stratification of cutaneous T-cell lymphomas in daily practice.
2. Integrate emerging tools, such as multiparameter flow cytometry, digital whole-slide image analysis and targeted genomics, to improve the classification and monitoring of primary cutaneous lymphomas.
3. Clarify how novel clinical entities and 'borderline' presentations beyond classical mycosis fungoides impact therapeutic decision-making and recommendations for patient follow-up.

<i>PLEASE CIRCLE YOUR RATING FOR EACH PRESENTER</i>	Met the stated learning objectives	Was unbiased and offered a balanced perspective	Improved my knowledge / under-standing of the topic	Was relevant to my practice	Provided opportunity for individual/group interaction
Julia J. Scarisbrick	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1
Emmanuela Guenova	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1
Melissa Pulitzer	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1
Ziba Rahbar	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1
Julia Dai	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1
Giorgio Alberto Croci	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1
Eleanor B. Ostroff	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1

KEY:

Strongly Agree / Very Good	Agree / Good	Neutral	Disagree / Poor	Strongly Disagree / Very poor
5	4	3	2	1

Which CanMEDS do you feel were covered by these topics? Select all that apply:

☐ Medical Expert ☐ Communicator ☐ Collaborator ☐ Health Advocate ☐ Leader ☐ Professional ☐ Scholar

What did you learn or how will this session impact your practice? _____

Additional Comments: _____

Session 4B: Integrating immune profiling with genomics to predict therapy response

Learning Objectives:

1. Describe how immune profiling of blood and skin informs disease biology and treatment response in CTCL.
2. Integrate genomic and clonality-based biomarkers into assessment of disease burden and therapeutic monitoring.
3. Apply emerging biomarker strategies to predict and evaluate response to mogamulizumab and other targeted therapies in CTCL

<i>PLEASE CIRCLE YOUR RATING FOR EACH PRESENTER</i>	Met the stated learning objectives	Was unbiased and offered a balanced perspective	Improved my knowledge / understanding of the topic	Was relevant to my practice	Provided opportunity for individual/group interaction
Hélène Moins-Teisserenc	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1
Christiane Querfeld	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1
Yenny Angela	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1
Woo Jin Lee	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1
Haiming Tang	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1
Katherine De Jong	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1
Denis Miyashiro	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1
Oleg Akilov	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1
Yamato Suemitsu	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1

Which CanMEDS do you feel were covered by these topics? Select all that apply:

☐ Medical Expert ☐ Communicator ☐ Collaborator ☐ Health Advocate ☐ Leader ☐ Professional ☐ Scholar

What did you learn or how will this session impact your practice? _____

Additional Comments: _____

KEY:

Strongly Agree / Very Good	Agree / Good	Neutral	Disagree / Poor	Strongly Disagree / Very poor
5	4	3	2	1

Plenary Session: Advances in Computational/Digital Pathology and AI in the Diagnosis of Cancer and Prediction of Prognosis

Learning Objectives:

Not available at the time of printing

*PLEASE CIRCLE YOUR RATING
FOR EACH PRESENTER
(see KEY at top of page)*

	Met the stated learning objectives	Was unbiased and offered a balanced perspective	Improved my knowledge / under-standing of the topic	Was relevant to my practice	Provided opportunity for individual / group interaction
Jason Hipp	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1

Which CanMEDS do you feel were covered by these topics? Select all that apply:

☐ Medical Expert ☐ Communicator ☐ Collaborator ☐ Health Advocate ☐ Leader ☐ Professional ☐ Scholar

What did you learn or how will this session impact your practice? _____

Additional Comments: _____

Session 5: Cutaneous Lymphoma International Consortium: Together we can

Learning Objectives:

1. Appreciate that international collaborations are feasible and productive in generating large datasets in rare lymphomas
2. Recognize meaningful prognostic factors and treatment profiles and impact in CTCL utilizing international collective data

*PLEASE CIRCLE YOUR RATING
FOR EACH PRESENTER*

	Met the stated learning objectives	Was unbiased and offered a balanced perspective	Improved my knowledge / under-standing of the topic	Was relevant to my practice	Provided opportunity for individual / group interaction
Youn H. Kim	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1
Gabriele Rocuzzo	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1
Abraham E. Bashir	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1
Zhuojing Chen	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1
Abraham E. Bashir	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1

Which CanMEDS do you feel were covered by these topics? Select all that apply:

☐ Medical Expert ☐ Communicator ☐ Collaborator ☐ Health Advocate ☐ Leader ☐ Professional ☐ Scholar

What did you learn or how will this session impact your practice? _____

Additional Comments: _____

KEY:

Strongly Agree / Very Good	Agree / Good	Neutral	Disagree / Poor	Strongly Disagree / Very poor
5	4	3	2	1

Session 6: Novel Targets for CTCL Treatments

Learning Objectives:

1. Identify and validate novel targets for the treatment of cutaneous T cell lymphoma.
2. Clarify the use of new treatments.

<i>PLEASE CIRCLE YOUR RATING FOR EACH PRESENTER</i>	Met the stated learning objectives	Was unbiased and offered a balanced perspective	Improved my knowledge / under-standing of the topic	Was relevant to my practice	Provided opportunity for individual/group interaction
Neha Mehta-Shah	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1
Stefan Barta	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1
Emmanuella Guenova	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1
Swaminathan Iyer	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1
Lilach Moyal	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1
Oleg Akilov	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1
Krithika Nayudu	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1

Which CanMEDS do you feel were covered by these topics? Select all that apply:

☐ Medical Expert ☐ Communicator ☐ Collaborator ☐ Health Advocate ☐ Leader ☐ Professional ☐ Scholar

What did you learn or how will this session impact your practice? _____

Additional Comments: _____

ACCREDITED SYMPOSIUM: Bridging the Gap: Advancing diagnosis and management of CTCL through collaborative multidisciplinary care

Learning Objectives:

1. Recognize suspected CTCL by identifying diagnostic challenges and interpret the clinical and histopathological features of MF and SS using staging and diagnostic tools.
2. Outline effective referral pathways for suspected CTCL, enabling timely multidisciplinary collaboration while incorporating patient perspectives.
3. Apply multidisciplinary insights to assess disease and patient characteristics that inform CTCL management and treatment decisions.

<i>PLEASE CIRCLE YOUR RATING FOR EACH PRESENTER</i>	Met the stated learning objectives	Was unbiased and offered a balanced perspective	Improved my knowledge / under-standing of the topic	Was relevant to my practice	Provided opportunity for individual/group interaction
Alejandro Gru	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1
Steven M. Horwitz	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1
Julia J. Scarisbrick	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1
Randy Gaw	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1

Which CanMEDS do you feel were covered by these topics? Select all that apply:

☐ Medical Expert ☐ Communicator ☐ Collaborator ☐ Health Advocate ☐ Leader ☐ Professional ☐ Scholar

What did you learn or how will this session impact your practice? _____

Additional Comments: _____

KEY:

Strongly Agree / Very Good	Agree / Good	Neutral	Disagree / Poor	Strongly Disagree / Very poor
5	4	3	2	1

Session 7A: Young Investigators Presentations: Risk, Disparities, and Disease Behavior in Cutaneous Lymphomas

Learning Objectives:

1. Describe epidemiologic risks and secondary malignancy patterns in patients with cutaneous lymphomas.
2. Recognize biologic and clinical factors, including microbial influences and phenotype, that contribute to disease severity and heterogeneity.
3. Interpret prognostic indicators across CTCL and related entities, including extracutaneous progression and transplant-related outcomes.

<i>PLEASE CIRCLE YOUR RATING FOR EACH PRESENTER</i>	Met the stated learning objectives	Was unbiased and offered a balanced perspective	Improved my knowledge / understanding of the topic	Was relevant to my practice	Provided opportunity for individual/group interaction
Karolina Wojewoda	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1
Amy S. Kaku	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1
Lindi Korpelshoek	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1
Christoph Iselin	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1
Stephanie K. Lin	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1
Brigit A. Lapolla	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1

Which CanMEDS do you feel were covered by these topics? Select all that apply:

☐ Medical Expert ☐ Communicator ☐ Collaborator ☐ Health Advocate ☐ Leader ☐ Professional ☐ Scholar

What did you learn or how will this session impact your practice? _____

Additional Comments: _____

Session 7B: "The Great Transformation": LCT and predicting CTCL outcomes

Learning Objectives:

1. Describe clinical indicators of poor outcome and progression in CTCL
2. Define the clinical and molecular features of LCT

<i>PLEASE CIRCLE YOUR RATING FOR EACH PRESENTER</i>	Met the stated learning objectives	Was unbiased and offered a balanced perspective	Improved my knowledge / understanding of the topic	Was relevant to my practice	Provided opportunity for individual/group interaction
Fabio Ianelli	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1
Haris Qureshi	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1
Belinda A. Campbell	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1
Risabh Lohray	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1
Sarah M. Gonzalez	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1
Marie Beylot-Barry	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1

Which CanMEDS do you feel were covered by these topics? Select all that apply:

☐ Medical Expert ☐ Communicator ☐ Collaborator ☐ Health Advocate ☐ Leader ☐ Professional ☐ Scholar

What did you learn or how will this session impact your practice? _____

Additional Comments: _____

KEY:

Strongly Agree / Very Good	Agree / Good	Neutral	Disagree / Poor	Strongly Disagree / Very poor
5	4	3	2	1

Session 8A: More Than Skin Deep: Patient Perspectives in Cutaneous Lymphoma

Learning Objectives:

1. Identify strategies to incorporate patient perspectives into clinical decision-making and care planning.
2. Recognize the importance of patient-centered care in the management of cutaneous lymphoma and how this may elevate patient quality of life.

<i>PLEASE CIRCLE YOUR RATING FOR EACH PRESENTER</i>	Met the stated learning objectives	Was unbiased and offered a balanced perspective	Improved my knowledge / under-standing of the topic	Was relevant to my practice	Provided opportunity for individual/group interaction
Jenny J. Park	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1
Julia J. Scarisbrick	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1
Alyssa Wu	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1
Manda D. Mootien	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1
Amirtha Rajasekaran	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1

Which CanMEDS do you feel were covered by these topics? Select all that apply:

☐ Medical Expert ☐ Communicator ☐ Collaborator ☐ Health Advocate ☐ Leader ☐ Professional ☐ Scholar

What did you learn or how will this session impact your practice? _____

Additional Comments: _____

Session 8B: Evolving Perspectives in Cutaneous T-Cell Lymphoma: From Traditional Histopathology to Advanced Diagnostic and Biological Insights

Learning Objectives:

1. Understand new techniques for diagnosis of cutaneous T-cell lymphoma
2. Appreciate the complexity of cutaneous T- cell lymphoma and where diagnoses may overlap.

<i>PLEASE CIRCLE YOUR RATING FOR EACH PRESENTER</i>	Met the stated learning objectives	Was unbiased and offered a balanced perspective	Improved my knowledge / under-standing of the topic	Was relevant to my practice	Provided opportunity for individual/group interaction
Paola Ghione	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1
Patrick Brunner	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1
Yi-Chien Tsai	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1
Anne M. Schrader	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1
Emma Johnson	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1
Giorgio Alberto Croci	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1

Which CanMEDS do you feel were covered by these topics? Select all that apply:

☐ Medical Expert ☐ Communicator ☐ Collaborator ☐ Health Advocate ☐ Leader ☐ Professional ☐ Scholar

What did you learn or how will this session impact your practice? _____

Additional Comments: _____

KEY:

Strongly Agree / Very Good	Agree / Good	Neutral	Disagree / Poor	Strongly Disagree / Very poor
5	4	3	2	1

Session 9A: Old Treatments Performing New Tricks

Learning Objectives:

1. Describe the efficacy and adverse effects of available therapeutics in the treatment of cutaneous lymphomas
2. Understand the spectrum of use of some older therapeutics in the management of cutaneous T and B cell lymphomas

<i>PLEASE CIRCLE YOUR RATING FOR EACH PRESENTER</i>	Met the stated learning objectives	Was unbiased and offered a balanced perspective	Improved my knowledge / under-standing of the topic	Was relevant to my practice	Provided opportunity for individual/group interaction
Samer A. Srouf	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1
Julia J. Scarisbrick	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1
Christina Cruz	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1
Sarah J. Lange	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1
Jori Hardin	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1
Ahmadou B. El Alaoui	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1
Teruyoshi Hisamoto	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1
Pietro Quaglino	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1
Jan P. Nicolay	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1
Marie Chevalier	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1

Which CanMEDS do you feel were covered by these topics? Select all that apply:

☐ Medical Expert ☐ Communicator ☐ Collaborator ☐ Health Advocate ☐ Leader ☐ Professional ☐ Scholar

What did you learn or how will this session impact your practice? _____

Additional Comments: _____

Session 9B: Patient Case Viewing and Discussions

Learning Objectives:

1. Recognize the clinical heterogeneity of cutaneous T-cell lymphomas (CTCL) across diverse populations and presentations, including atypical and geographically influenced disease patterns.
2. Identify key diagnostic challenges in CTCL, including distinguishing rare variants (e.g., gamma-delta phenotype, CD8+ subtypes) and differentiating CTCL from mimickers such as angioedema, infections, or other malignancies.
3. Interpret unusual anatomical presentations of CTCL, including ocular, genital, and perigenital involvement, and understand their implications for diagnosis and management.
4. Apply insights from case-based learning to improve clinical reasoning, early recognition, and management strategies for rare and atypical lymphoproliferative disorders.

<i>PLEASE CIRCLE YOUR RATING FOR EACH PRESENTER</i>	Met the stated learning objectives	Was unbiased and offered a balanced perspective	Improved my knowledge / under-standing of the topic	Was relevant to my practice	Provided opportunity for individual/group interaction
Prince Agyemang	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1
Risabh Lohray	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1
Lauren Spadt	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1
Katherine de Jong	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1

KEY:

Strongly Agree / Very Good	Agree / Good	Neutral	Disagree / Poor	Strongly Disagree / Very poor
5	4	3	2	1

Jacqueline Junkins-Hopkins	5	4	3	2	1	5	4	3	2	1	5	4	3	2	1	5	4	3	2	1	5	4	3	2	1
Ivan V. Litvinov	5	4	3	2	1	5	4	3	2	1	5	4	3	2	1	5	4	3	2	1	5	4	3	2	1
Emmanuella Guenova	5	4	3	2	1	5	4	3	2	1	5	4	3	2	1	5	4	3	2	1	5	4	3	2	1
Eleanor B. Ostroff	5	4	3	2	1	5	4	3	2	1	5	4	3	2	1	5	4	3	2	1	5	4	3	2	1
Sarah M. Gonzalez	5	4	3	2	1	5	4	3	2	1	5	4	3	2	1	5	4	3	2	1	5	4	3	2	1
Karla Katrina T. Cajigal	5	4	3	2	1	5	4	3	2	1	5	4	3	2	1	5	4	3	2	1	5	4	3	2	1

Which CanMEDS do you feel were covered by these topics? Select all that apply:

☐ Medical Expert ☐ Communicator ☐ Collaborator ☐ Health Advocate ☐ Leader ☐ Professional ☐ Scholar

What did you learn or how will this session impact your practice? _____

Additional Comments: _____

Session 10: Challenging Assumptions in Cutaneous Lymphomas: A Debate Series

Learning Objectives:

1. Clarify evolving diagnostic boundaries in CTCL by examining expert debates on SPTCL classification, Sézary syndrome presentations, and pediatric CTCL evaluation.
2. Apply current evidence to differentiate challenging CTCL presentations, including blood involvement without erythroderma, in order to improve diagnostic accuracy and clinical decision-making.
3. Integrate prognostic indicators into the management of early-stage MF and evaluate whether treatment strategies should be modified at disease onset.

<i>PLEASE CIRCLE YOUR RATING FOR EACH PRESENTER</i>	Met the stated learning objectives	Was unbiased and offered a balanced perspective	Improved my knowledge / understanding of the topic	Was relevant to my practice	Provided opportunity for individual/group interaction
Michael Girardi	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1
Joan Guitart	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1
Chalid Assaf	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1
Jade Cury Martins	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1
Maarten Vermeer	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1
Emmilia Hodack	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1
Pablo Ortiz-Romero	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1

Which CanMEDS do you feel were covered by these topics? Select all that apply:

☐ Medical Expert ☐ Communicator ☐ Collaborator ☐ Health Advocate ☐ Leader ☐ Professional ☐ Scholar

What did you learn or how will this session impact your practice? _____

Additional Comments: _____

KEY:

Strongly Agree / Very Good	Agree / Good	Neutral	Disagree / Poor	Strongly Disagree / Very poor
5	4	3	2	1

Session 11: Best of Congress

Learning Objectives:

1. Summarize key advances and high-impact findings presented across multiple sessions of the Congress, as identified by expert Co-Chairs.
2. Integrate selected best-practice insights into clinical decision-making and future research directions in cutaneous lymphomas.

PLEASE CIRCLE YOUR RATING FOR EACH PRESENTER	Met the stated learning objectives	Was unbiased and offered a balanced perspective	Improved my knowledge / under-standing of the topic	Was relevant to my practice	Provided opportunity for individual/group interaction
Emmanuela Guenova	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1
José A. Sanches	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1
Chalid Assaf	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1	5 4 3 2 1

Which CanMEDS do you feel were covered by these topics? Select all that apply:

- ☐ Medical Expert
☐ Communicator
☐ Collaborator
☐ Health Advocate
☐ Leader
☐ Professional
☐ Scholar

What did you learn or how will this session impact your practice?

Additional Comments:

Overall Evaluation

KEY:	Strongly Agree / Very Good	Agree / Good	Neutral	Disagree / Poor	Strongly Disagree / Very poor
	5	4	3	2	1

PLEASE CIRCLE YOUR RATING FOR THE FOLLOWING:

Please indicate your rating of the following:					
Delegates were able to enjoy a participative and stimulating program	5	4	3	2	1
Delegates were able to network and exchange ideas	5	4	3	2	1
Please rate the overall content of the program	5	4	3	2	1
Le Westin Montréal					
a) Accommodations	5	4	3	2	1
b) Meeting Rooms	5	4	3	2	1
c) Location	5	4	3	2	1
Overall, the congress was well-organized					
	5	4	3	2	1

Topics / areas I would like to see covered at future events: _____

What improvements can we make: _____

Which presentations had the most impact on you and why? _____

Describe any changes you are prepared to make to your practice because of the session's presentations _____

Other comments: _____
